{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:52:39Z","timestamp":1761706359441,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.cellimm.2017.01.003","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T23:41:11Z","timestamp":1483659671000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38"],"prefix":"10.1016","volume":"313","author":[{"given":"Ronit","family":"Mazor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilad","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youjin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kreitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2017.01.003_b0005","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.1188\/12.CJON.E164-E172","article-title":"Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma","volume":"16","author":"McCann","year":"2012","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.cellimm.2017.01.003_b0010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.beha.2015.09.003","article-title":"Immunoconjugates in the management of hairy cell leukemia","volume":"28","author":"Kreitman","year":"2015","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1172\/JCI111379","volume":"73","author":"Waldmann","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2017.01.003_b0020","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.2174\/138161209788923949","article-title":"Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies","volume":"15","author":"Kreitman","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cellimm.2017.01.003_b0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"Mazor","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2017.01.003_b0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.cellimm.2017.01.003_b0035","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/bjc.2016.84","article-title":"Countering immunotoxin immunogenicity","volume":"114","author":"Flavell","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2017.01.003_b0040","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1200\/JCO.2004.01.127","article-title":"Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer","volume":"22","author":"Bishop","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0045","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-15-1412","article-title":"Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity","volume":"22","author":"Kreitman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2017.01.003_b0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cellimm.2015.10.008","article-title":"Engineering less immunogenic and antigenic FVIII proteins","volume":"301","author":"Pratt","year":"2016","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0060","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1038\/mtm.2015.21","article-title":"Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance","volume":"2","author":"Blazanovic","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.cellimm.2017.01.003_b0065","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1073\/pnas.1014739108","article-title":"Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift","volume":"108","author":"Cantor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cellimm.2017.01.003_b0070","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.4049\/jimmunol.174.6.3187","article-title":"Rationally engineered therapeutic proteins with reduced immunogenicity","volume":"174","author":"Tangri","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0075","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Mazor","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cellimm.2017.01.003_b0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2015.06.003","article-title":"Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A","volume":"425","author":"Mazor","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cellimm.2017.01.003_b0085","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood.V83.2.426.426","article-title":"Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma","volume":"83","author":"Kreitman","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2017.01.003_b0090","doi-asserted-by":"crossref","first-page":"E3597","DOI":"10.1073\/pnas.1218138109","article-title":"Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"109","author":"Mazor","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cellimm.2017.01.003_b0095","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1073\/pnas.93.3.974","article-title":"Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation","volume":"93","author":"Kuan","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cellimm.2017.01.003_b0100","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2014.06.014","article-title":"An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies","volume":"38","author":"Bera","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cellimm.2017.01.003_b0105","first-page":"503","article-title":"Recombinant immunotoxins in the treatment of cancer","volume":"248","author":"Pastan","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0110","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/protein\/7.5.697","article-title":"Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv","volume":"7","author":"Reiter","year":"1994","journal-title":"Protein Eng."},{"key":"10.1016\/j.cellimm.2017.01.003_b0115","first-page":"318","article-title":"Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors","volume":"55","author":"Webber","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2017.01.003_b0120","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","article-title":"A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity","volume":"113","author":"Weldon","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2017.01.003_b0125","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1535-7163.MCT-15-0532","article-title":"Recombinant immunotoxin with T-cell epitope mutations that greatly reduce immunogenicity for treatment of mesothelin-expressing tumors","volume":"14","author":"Mazor","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellimm.2017.01.003_b0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-12-0336","article-title":"A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity","volume":"12","author":"Weldon","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellimm.2017.01.003_b0135","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","article-title":"Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity","volume":"68","author":"Du","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2017.01.003_b0140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00251-011-0513-0","article-title":"Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes","volume":"63","author":"Greenbaum","year":"2011","journal-title":"Immunogenetics"},{"key":"10.1016\/j.cellimm.2017.01.003_b0145","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1021\/acs.bioconjchem.5b00190","article-title":"Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"26","author":"Weldon","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.cellimm.2017.01.003_b0150","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.163.11.6072","article-title":"Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point","volume":"163","author":"Onda","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0155","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/327713a0","article-title":"Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope","volume":"327","author":"Allen","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2017.01.003_b0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/intimm\/8.2.177","article-title":"Identification of a putative motif for binding of peptides to HLA-DQ2","volume":"8","author":"Johansen","year":"1996","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0165","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/toxins7104067","article-title":"Mutagenic deimmunization of diphtheria toxin for use in biologic drug development","volume":"7","author":"Schmohl","year":"2015","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.cellimm.2017.01.003_b0170","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.chembiol.2015.04.017","article-title":"Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo","volume":"22","author":"Zhao","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.cellimm.2017.01.003_b0175","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1073\/pnas.1321126111","article-title":"Removing T-cell epitopes with computational protein design","volume":"111","author":"King","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874917300035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874917300035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:55:06Z","timestamp":1757804106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874917300035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":35,"alternative-id":["S0008874917300035"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2017.01.003","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2017.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}